Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.

Autor:	Bengtsson NE; Department of Neurology, University of Washington, Seattle, Washington 98195-7720, USA.; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA., Hall JK; Department of Neurology, University of Washington, Seattle, Washington 98195-7720, USA.; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA., Odom GL; Department of Neurology, University of Washington, Seattle, Washington 98195-7720, USA.; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA., Phelps MP; Department of Pathology, University of Washington, Seattle, Washington 98195-7720, USA., Andrus CR; Department of Medicine, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Genome Sciences, University of Washington, Seattle, Washington 98195-7720, USA., Hawkins RD; Department of Medicine, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Genome Sciences, University of Washington, Seattle, Washington 98195-7720, USA., Hauschka SD; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Biochemistry, University of Washington, Seattle, Washington 98195-7720, USA., Chamberlain JR; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Medicine, University of Washington, Seattle, Washington 98195-7720, USA., Chamberlain JS; Department of Neurology, University of Washington, Seattle, Washington 98195-7720, USA.; Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Medicine, University of Washington, Seattle, Washington 98195-7720, USA.; Department of Biochemistry, University of Washington, Seattle, Washington 98195-7720, USA.
Jazyk:	angličtina
Zdroj:	Nature communications [Nat Commun] 2017 Feb 14; Vol. 8, pp. 14454. Date of Electronic Publication: 2017 Feb 14.
DOI:	10.1038/ncomms14454
Abstrakt:	Gene replacement therapies utilizing adeno-associated viral (AAV) vectors hold great promise for treating Duchenne muscular dystrophy (DMD). A related approach uses AAV vectors to edit specific regions of the DMD gene using CRISPR/Cas9. Here we develop multiple approaches for editing the mutation in dystrophic mdx 4cv mice using single and dual AAV vector delivery of a muscle-specific Cas9 cassette together with single-guide RNA cassettes and, in one approach, a dystrophin homology region to fully correct the mutation. Muscle-restricted Cas9 expression enables direct editing of the mutation, multi-exon deletion or complete gene correction via homologous recombination in myogenic cells. Treated muscles express dystrophin in up to 70% of the myogenic area and increased force generation following intramuscular delivery. Furthermore, systemic administration of the vectors results in widespread expression of dystrophin in both skeletal and cardiac muscles. Our results demonstrate that AAV-mediated muscle-specific gene editing has significant potential for therapy of neuromuscular disorders.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu